Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 4/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.47 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.47 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.45 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 2/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL299098 | 0.93 | CYP3A4 (0.51) | PIK3CACYP3A4CYP2C9CYP2C19MAP2K7 | |
| SCHEMBL297360 | 0.90 | CYP2C9 (0.56) | PIK3CACYP2C9CYP2C19BRAFRIPK1 | |
| SCHEMBL409620 | 0.89 | CYP2C9 (0.54) | PIK3CACYP3A4CYP2C9CYP2C19BRAF | |
| SCHEMBL298660 | 0.89 | PIK3CA (0.57) | PIK3CACYP3A4MAP2K7MAP2K4NTRK1 | |
| SCHEMBL298449 | 0.87 | CYP2C9 (0.53) | PIK3CACYP3A4CYP2C9CYP2C19BRAF | |
| SCHEMBL299292 | 0.85 | CYP3A4 (0.50) | PIK3CACYP3A4CYP2C9CYP2C19BRAF | |
| SCHEMBL299069 | 0.85 | CYP3A4 (0.57) | PIK3CACYP3A4CYP2C9CYP2C19MAP2K7 | |
| SCHEMBL415675 | 0.84 | CYP2C9 (0.52) | PIK3CACYP2C9CYP2C19BRAFRIPK1 | |
| SCHEMBL299140 | 0.84 | CYP2C19 (0.59) | PIK3CACYP2C9CYP2C19BRAFCYP2D6 | |
| SCHEMBL298060 | 0.83 | CYP2C9 (0.51) | PIK3CACYP2C9CYP2C19NTRK1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| EP-2427433-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | Plexxikon, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | PIK3CA 277/4885CYP3A4 3611/4885CYP2C9 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.